

# Health of Patients' Eyes in Glaucoma Clinics: HOPE Glaucoma

<b>Submission date</b> 22/08/2013	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 22/08/2013	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 07/02/2017	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Ms Helen Fairlamb

**Contact details**  
Cumberland Infirmary  
Newtown Road  
Carlisle  
United Kingdom  
CA2 7HY  
-  
helen.fairlamb@ncuh.nhs.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
14767

# Study information

## Scientific Title

Health of Patients' Eyes in Glaucoma Clinics: HOPE Glaucoma

## Acronym

HOPE Glaucoma

## Study objectives

Glaucoma involves progressive optic nerve fibre loss, subsequently leading to irreversible and disabling visual field defects. In the UK alone, more than 200,000 patients have this condition. Glaucoma patients need to be followed-up periodically, which means it is a large financial and resource burden to the NHS. Glaucoma has a history of poor therapy adherence and lack of patient knowledge of their condition is frequently cited as a cause (Grey et al. 2010). In this study the aim is to assess whether providing patients with a client-held eye health summary (a personal record of their condition) improves patients' knowledge about their disorder and subsequently has a beneficial impact on the rate of deterioration of their eye(s). The hypothesis is that improved disease knowledge, through the introduction of a fairly simple and cheap patient-held tool, improves awareness and contributes to positive behavioral change in patients.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

First MREC approval date 28/09/2012, ref: 12/YH/0471

## Study design

Randomised; Interventional; Design type: Not specified

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Quality of life

## Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

## Health condition(s) or problem(s) studied

Topic: Eye; Subtopic: Eye (all Subtopics); Disease: Glaucoma

## Interventions

Not provided at time of registration

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome measure**

Not provided at time of registration

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

10/06/2013

**Completion date**

10/06/2014

**Eligibility****Key inclusion criteria**

1. Adult (age > 18 years)
  2. Patients diagnosed with glaucoma, to include the following three diseases:
    - 2.1. Ocular Hypertension (OHT): Intra ocular pressures raised above the normal range (more than or equal to 21 mmHg), but no signs of optic nerve fibre loss or visual field loss
    - 2.2. Suspected glaucoma (SG): Optic nerve fibre loss or visual field loss of both in presence of normal intraocular pressures
    - 2.3. Chronic Open Angle Glaucoma (COAG): Any combination of raised intraocular pressures, optic nerve fibre loss and/or visual field loss
- Target Gender: Male & Female; Upper Age Limit 100 years ; Lower Age Limit 18 years

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

Planned Sample Size: 122; UK Sample Size: 122

**Key exclusion criteria**

1. Under age (< 18 years)
2. Mental incapacity through inability to read, co-morbidities (e.g. severe stroke, advanced dementia) or any other contributing factor

3. Inability to provide informed written consent
4. Unable to speak or understand English since interpreter is not available throughout the course of the study

**Date of first enrolment**

10/06/2013

**Date of final enrolment**

10/06/2014

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Cumberland Infirmary**

Carlisle

United Kingdom

CA2 7HY

## **Sponsor information**

**Organisation**

North Cumbria University Hospitals NHS Trust (UK)

**Sponsor details**

West Cumberland Hospital

Hensingham Whitehaven

Cumbria

England

United Kingdom

CA28 8JG

**Sponsor type**

Hospital/treatment centre

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

International Glaucoma Association (UK)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>	protocol	07/08/2015		Yes	No
<a href="#">Results article</a>	results	30/08/2017		Yes	No